Design Therapeutics (DSGN) EBT Margin (2020)
Design Therapeutics recorded quarterly EBT Margin of 11700.0% in Q4 2020, up 1.8% quarter-over-quarter from 11915.0% in Q3 2020.
Design Therapeutics' EBT Margin history runs 1 years deep, the most recent figure standing at 11700.0% for Q4 2020.
- In Q4 2020, EBT Margin changed N/A year-over-year to 11700.0%; the TTM figure through Dec 2020 stood at 3685.84% (changed N/A YoY), while the FY2020 annual figure was 3685.84%, changed N/A from the prior year.
- EBT Margin came in at 11700.0% for Q4 2020 at Design Therapeutics, up from 11915.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 438.73% in Q1 2020 to a low of 11915.0% in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -11,700.00% |
| Sep 30, 2020 | -11,915.00% |
| Jun 30, 2020 | -4,719.35% |
| Mar 31, 2020 | -438.73% |